Em recrutamento
FASE
Número Europeu 2018-001974-76 
MK-3475-630 KEYNOTE-630
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Detalhes
Destaques